DemeRx, Inc.

About DemeRx, Inc.

DemeRx is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of addiction, with a focus on revolutionizing addiction therapeutics and improving outcomes for individuals battling substance use disorders.

Products & Services

DMX-1001 (oral noribogaine):A promising investigational therapy for alcohol use disorder, affecting over 29 million people in the U.S.

Specialties

Addiction therapeutics Alcohol use disorder treatment Neuroplasticity research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 1700000 MR: - FA: $1.7 million FAN: 1700000	D: 2025-10-07 FD: 2025-10-07	1 investors

Grant Latest

2025-10-07

$1.7M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Deborah C. Mash

Chief Executive Officer and President, Board Member

M

Mark Ellison

President of Clinical Operations and Chief Development Officer

E

E. Douglas Kramer

Vice President, Clinical and Regulatory Affairs

J

John C. Thomas Jr.

Chief Financial Officer and Secretary

R

Richard S. Serbin

Executive Chairman of the Board

V

Vic Pirotsky

Board Member

View 19 more team members with Pro

Unlock Full Team Directory

Recent News

DemeRx, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised